Responses
Clinical/translational cancer immunotherapy
Original research
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Compose a Response to This Article
Other responses
No responses have been published for this article.